GE HealthCare Technologies reported second-quarter 2026 non-GAAP earnings of $1.13 per share, beating analyst estimates by $0.09, while revenue of $5.3 billion exceeded expectations by $40 million. Revenue grew 5.7% year-over-year, including organic revenue growth of 3.5%, driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions with overall strength in the U.S., Europe, the Middle East and Africa, and Rest of World, though Patient Care Solutions continued to be challenged. The company posted record organic orders growth of 11.1%, a book-to-bill ratio of 1.15 times, and a backlog of $23.9 billion. For the full year 2026, GE HealthCare reaffirmed its guidance, including organic revenue growth of 3.0% to 4.0%, adjusted EBIT margin of 15.4% to 15.7%, and adjusted EPS in the range of $4.80 to $5.00, representing 4.6% to 9.0% growth year-over-year. Shares rose 1% in pre-market trading.
GE HealthCare Technologies Inc.GE HealthCare beat Q2 earnings and revenue estimates, reported strong organic orders growth, and reaffirmed guidance.